J&J offers $5.5bn settlement in lawsuits claiming talc link to cancer

<p>Johnson & Johnson has agreed to a $5.5 billion settlement covering roughly 70,000 U.S. lawsuits alleging that its talc-based baby powder caused cancer. The figure is large, but the more telling number is the count of plaintiffs. A decade of litigation, regulatory pressure, and a 2023 bankruptcy maneuver that collapsed in court have converged on a single, expensive exit.</p><p>The settlement is structured as a subsidiary transaction through a Texas-based entity, a familiar J&J playbook: isolate the liability, fund it separately, and keep the parent company's broader product portfolio insulated from the headline. It is the same logic the company used when it spun off its consumer health unit, now Kenvue, before the worst of the talc verdicts landed.</p><p>For claimants, the math is straightforward. Divide $5.5 billion across 70,000 cases and the average payout lands near $78,000, before legal fees and administrative costs. That is a fraction of the billion-dollar jury verdicts J&J absorbed in state courts over the past several years, including a 2024 award that briefly pushed the company's market value down by tens of billions. The company is buying certainty at a discount to what continued trials could cost.</p><p>The deal still requires court approval and a critical mass of plaintiffs to opt in. J&J has reserved the right to walk away if participation falls short, a contingency that signals confidence the offer is generous enough to clear the bar. For investors, the takeaway is narrower than the headline suggests: a known liability is being priced, not a new one being discovered.</p>